In Vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 1046-1053

  Villegas Mendez, Ana ^a,b   Garin, Marina I ^b   Pineda Molina, Estela ^c   Veratti, Eugenia ^a   Bueren, Juan A ^b   Fender, Pascal ^c   Lenormand, Jean Luc ^a  

^a LABORATOIRE TIMC IMAG   (France)

^b CIEMAT   (Spain)

^c CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; ANTIGEN; CANCER VACCINE; OVALBUMIN; PENTON DODECAHEDRON VECTOR; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; CANCER REGRESSION; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN ENGINEERING; TUMOR IMMUNITY; VIRUS LIKE AGENT; VIRUS MORPHOLOGY;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 3; MUS;

EID: 77952011654     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.16     Document Type: Article

References (43)

1. Tacken, PJ, de Vries, IJ, Torensma, R and Figdor, CG (2007). Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790-802.
2. Epaulard, O, Toussaint, B, Quenee, L, Derouazi, M, Bosco, N, Villiers, C et al. (2006). Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector. Mol Ther 14:656-661.
3. Radford, KJ, Higgins, DE, Pasquini, S, Cheadle, EJ, Carta, L, Jackson, AM et al. (2002). A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther 9:1455-1463.
4. Nishikawa, H, Sato, E, Briones, G, Chen, LM, Matsuo, M, Nagata, Y et al. (2006). In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 116:1946-1954.
5. Jäger, E, Karbach, J, Gnjatic, S, Neumann, A, Bender, A, Valmori, D et al. (2006). Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103:14453-14458.
6. Orlandi, F, Venanzi, FM, Concetti, A, Yamauchi, H, Tiwari, S, Norton, L et al. (2007). Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 13:6195-6203.
7. Julien, S, Picco, G, Sewell, R, Vercoutter-Edouart, AS, Tarp, M, Miles, D et al. (2009). Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br J Cancer 100:1746-1754.
8. Kafri, T, Morgan, D, Krahl, T, Sarvetnick, N, Sherman, L and Verma, I (1998). Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 95:11377-11382.
9. Molinier-Frenkel, V, Gahery-Segard, H, Mehtali, M, Le Boulaire, C, Ribault, S, Boulanger, P et al. (2000). Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 74:7678-7682.
10. Molinier-Frenkel, V, Le Boulaire, C, Le Gal, FA, Gahéry-Segard, H, Tursz, T, Guillet, JG et al. (2000). Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum Gene Ther 11:1911-1920.
11. Molinier-Frenkel, V, Lengagne, R, Gaden, F, Hong, SS, Choppin, J, Gahery-Ségard, H et al. (2002). Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 76:127-135.
12. Fender, P, Ruigrok, RW, Gout, E, Buffet, S and Chroboczek, J (1997). Adenovirus dodecahedron, a new vector for human gene transfer. Nat Biotechnol 15:52-56.
13. Hong, SS, Gay, B, Karayan, L, Dabauvalle, MC and Boulanger, P (1999). Cellular uptake and nuclear delivery of recombinant adenovirus penton base. Virology 262:163-177.
14. Smith, CC, Kulka, M and Aurelian, L (2000). Modified adenovirus penton base protein (UTARVE) as a non-replicating vector for delivery of antisense oligonucleotides with antiviral and/or antineoplastic activity. Int J Oncol 17:841-850.
15. Fender, P, Schoehn, G, Foucaud-Gamen, J, Gout, E, Garcel, A, Drouet, E et al. (2003). Adenovirus dodecahedron allows large multimeric protein transduction in human cells. J Virol 77:4960-4964.
16. Garcel, A, Gout, E, Timmins, J, Chroboczek, J and Fender, P (2006). Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors. J Gene Med 8:524-531.
17. Vivès, RR, Lortat-Jacob, H, Chroboczek, J and Fender, P (2004). Heparan sulfate proteoglycan mediates the selective attachment and internalization of serotype 3 human adenovirus dodecahedron. Virology 321:332-340.
18. Fender, P, Schoehn, G, Perron-Sierra, F, Tucker, GC and Lortat-Jacob, H (2008). Adenovirus dodecahedron cell attachment and entry are mediated by heparan sulfate and integrins and vary along the cell cycle. Virology 371:155-164.
19. Galinier, R, Gout, E, Lortat-Jacob, H, Wood, J and Chroboczek, J (2002). Adenovirus protein involved in virus internalization recruits ubiquitin-protein ligases. Biochemistry 41:14299-14305.
20. Bellone, M, Cantarella, D, Castiglioni, P, Crosti, MC, Ronchetti, A, Moro, M et al. (2000). Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 165:2651-2656.
21. Shibagaki, N and Udey, MC (2002). Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 168:2393-2401.
22. Rötzschke, O, Falk, K, Stevanovic, S, Jung, G, Walden, P and Rammensee, HG (1991). Exact prediction of a natural T cell epitope. Eur J Immunol 21:2891-2894.
23. Cubas, R, Zhang, S, Kwon, S, Sevick-Muraca, EM, Li, M, Chen, C et al. (2009). Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother 32:118-128.
24. Manolova, V, Flace, A, Bauer, M, Schwarz, K, Saudan, P and Bachmann, MF (2008). Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 38:1404-1413.
25. Greber, UF, Willetts, M, Webster, P and Helenius, A (1993). Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75:477-486.
26. Wohlfart, C (1988). Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 62:2321-2328.
27. Appay, V, Douek, DC and Price, DA (2008). CD8+ T cell efficacy in vaccination and disease. Nat Med 14:623-628.
28. Dzutsev, AH, Belyakov, IM, Isakov, DV, Margulies, DH and Berzofsky, JA (2007). Avidity of CD8 T cells sharpens immunodominance. Int Immunol 19:497-507.
29. Peng, G, Guo, Z, Kiniwa, Y, Voo, KS, Peng, W, Fu, T et al. (2005). Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309:1380-1384.
30. Molinier-Frenkel, V, Prévost-Blondel, A, Hong, SS, Lengagne, R, Boudaly, S, Magnusson, MK et al. (2003). The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain. J Biol Chem 278:37175-37182.
31. Naskalska, A, Szolajska, E, Chaperot, L, Angel, J, Plumas, J and Chroboczek J (2009). Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron. Vaccine 27:7385-7393.
32. Ruedl, C, Storni, T, Lechner, F, Bächi, T and Bachmann, MF (2002). Cross-presentation of virus-like particles by skin-derived CD8 (-) dendritic cells: a dispensable role for TAP. Eur J Immunol 32:818-825.
33. Bright, RA, Carter, DM, Daniluk, S, Toapanta, FR, Ahmad, A, Gavrilov, V et al. (2007). Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878.
34. Singh, R and Kostarelos, K (2009). Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol 27:220-229.
35. Ruedl, C, Schwarz, K, Jegerlehner, A, Storni, T, Manolova, V and Bachmann, MF (2005). J Virol 79:717-724.
36. Allsopp, CE, Plebanski, M, Gilbert, S, Sinden, RE, Harris, S, Frankel, G et al. (1996). Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 26:1951-1959.
37. Sedlik, C, Saron, M, Sarraseca, J, Casal, I and Leclerc, C (1997). Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 94:7503-7508.
38. Guo, L, Lu, X, Kang, SM, Chen, C, Compans, RW and Yao, Q (2003). Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology 313:502-513.
39. Sedlik, C, Dadaglio, G, Saron, MF, Deriaud, E, Rojas, M, Casal, SI et al. (2000). In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 74:5769-5775.
40. Boisgérault, F, Rueda, P, Sun, CM, Hervas-Stubbs, S, Rojas, M and Leclerc, C (2005). Cross-priming of T cell responses by synthetic microspheres carrying a CD8+ T cell epitope requires an adjuvant signal. J Immunol 174:3432-3439.
41. Singh, R and Paterson, Y (2007). Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 67:1887-1892.
42. Elkord, E, Dangoor, A, Burt, DJ, Southgate, TD, Daayana, S, Harrop, R et al. (2009). Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother 58:1657-1667.
43. Fuschiotti, P, Schoehn, G, Fender, P, Fabry, CM, Hewat, EA, Chroboczek, J et al. (2006). Structure of the dodecahedral penton particle from human adenovirus type 3. J Mol Biol 356:510-520.